Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Open-Label, Phase 3 Study to Evaluate Imetelstat (GRN163L) Versus Best Available Therapy (BAT) in Patients With Intermediate-2 or High-risk Myelofibrosis (MF) Relapsed / Refractory (R/R) to Janus Kinase (JAK) Inhibitor

NCT04576156 is registered in ClinicalTrials.gov with Geron Corporation as lead sponsor.

NCT NCT04576156
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04576156 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Open-Label, Phase 3 Study to Evaluate Imetelstat (GRN163L) Versus Best Available Therapy (BAT) in Patients With Intermediate-2 or High-risk Myelofibrosis (MF) Relapsed / Refractory (R/R) to Janus Kinase (JAK) Inhibitor
Lead sponsor
Geron Corporation
Phase
Phase 3
Overall status
Active, not recruiting
Start date
April 12, 2021
Completion date
June 30, 2028
Enrollment
327 (actual)
Sites
144

Conditions

As the registry lists them; a condition with its own page is linked.

myelofibrosis